Ginkgo Bioworks Holdings, Inc.
corporate_fare Company Profile
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 10 items for DNA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 10 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for DNA spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Ginkgo 10-Q: Q3 Loss Narrows to $41M, $285M Liquidity Funds 12+ Months
- Ginkgo Q3 Revenue $28M, Loss Narrows to $41M; First Autonomous Lab Sale to Novo
- Ginkgo Posts Narrower Q3 Loss, Lands First Autonomous Lab Sale to Pharma Giant Novo
- Ginkgo Bioworks Q2 Revenue Halves to $20M, Cash Runway Tightens as $47M Gets Locked Up
- Ginkgo Bioworks Reports 49% Revenue Decline, Q1 Loss; $47M Cash Restricted Post-Quarter
Financial Snapshot
Short Interest & Short Volume
3.85 days to coverFINRA reported short interest of 9,490,310 shares in DNA as of the October 30, 2026 settlement, a 14.4% increase from the prior period — about 3.9 days to cover at its recent average daily volume. On November 20, 2026, 64.2% of DNA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.